mTORMammalian Target of Rapamycin (a protein)
mTORMan, Technology, Organisation and Risk Management
References in periodicals archive ?
Previous studies have shown that mutations in AKT3, PIK3CA and mTOR genes are associated with iHME.
After being blocked with 5% non-fat milk for 2 h at room temperature, the membranes were respectively incubated with primary antibodies against Akt (4691), phosphorylated Akt (p-Akt, 4060), mechanistic target of rapamycin (mTOR, 2972), phosphorylated mTOR (p-mTOR, 5536), mitogen-activated protein kinase (MAPK, 8690), phosphorylated MAPK (p-MAPK, 4511), matrix metalloproteinase (MMP)-2 (13132), MMP-9 (13667) and [beta]-actin (4970) (all from Cell Signaling Technology, USA) at 4[degrees]C overnight.
The mTOR downstream signaling pathway contains two key substrates, the ribosomal S6 kinase (S6K) and the eukaryotic translational initiation factor 4E binding protein 1 (4E-BP1).
For example, a recent case report [13] in the SAMJ was clearly a case of an adolescent with TSC, facial angiofibromas and a presumed fat-poor angiomyolipoma (a non-cancerous tumour that should be treated with an mTOR inhibitor).
So far, reducing the expression of mTOR has been shown to extend lifespan across multiple species.
The effects of rapamycin on mTOR phosphorylation and autophagic induction were confirmed by western blotting and immunofluorescence staining (see sections below).
We further explore the molecular mechanisms, that is, induction of cytotoxicity and autophagy mediated by ROS generation and mTOR signaling pathway.
These proteins inhibit the mTOR pathway which regulates cell growth and differentiation.
A fosforilacao de mTOR e a consequente cascata bioquimica de reacoes de anabolismo pode ser melhorada pelo consumo de aminoacidos essenciais, dentre os quais se destaca a leucina, podendo entao potencializar a sintese de proteinas miofibrilares (hipertrofia).
Even for patients who have already had difficulty with skin cancer formation, mTOR inhibition appears to be of benefit," the authors wrote.
It has been reported that blockade of mTOR with its specific inhibitor CCI-779 stimulates autophagy and eliminates the activation of RIPKs in RCC4 cells [16].
A favorable risk/benefit ratio needs to be demonstrated in clinic trials to be sure that mTOR inhibitors such as rapamycin have acceptable safety and efficacy in aging-related conditions in humans.